Warfarin will soon have a label saying that people with certain genetic variations should start off with a lower initial dose of the blood thinner, reports the Wall Street Journal. Adding this label is part of the Food and Drug Administration's push to promote using genetics to predict patient's reactions to medicine, a major tenet of personalized medicine. This stance, though, is pitting the FDA against major insurers in the US that do not cover the tests.
The Line in the Sand Over Personalized Medicine Is Drawn
Aug 16, 2007